Most Liquid Pharmaceutical Products Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1MRNA Moderna
8.35 B
(0.04)
 4.04 
(0.16)
2DNLI Denali Therapeutics
1.07 B
 0.01 
 4.44 
 0.06 
3TLX Telix Pharmaceuticals Limited
745.86 M
 0.00 
 3.86 
(0.01)
4MRVI Maravai Lifesciences Holdings
617.45 M
 0.01 
 4.53 
 0.04 
5DVAX Dynavax Technologies
518.17 M
(0.16)
 3.04 
(0.48)
6MRUS Merus BV
376.11 M
 0.08 
 6.14 
 0.47 
7DSGN Design Therapeutics
359.38 M
 0.01 
 5.44 
 0.05 
8VALN Valneva SE ADR
336.22 M
(0.10)
 3.81 
(0.37)
9VERV Verve Therapeutics
293.56 M
 0.15 
 12.63 
 1.84 
10MOLN Molecular Partners AG
267.13 M
(0.05)
 4.75 
(0.23)
11FBIOP Fortress Biotech Pref
248.77 M
 0.11 
 3.80 
 0.43 
12MRSN Mersana Therapeutics
225.13 M
 0.02 
 7.67 
 0.16 
13MDGL Madrigal Pharmaceuticals
211.77 M
(0.10)
 2.35 
(0.24)
14LSBPW LakeShore Biopharma Co,
201.56 M
 0.06 
 20.36 
 1.31 
15MCRB Seres Therapeutics
195.8 M
(0.04)
 7.98 
(0.35)
16DTIL Precision BioSciences
184.14 M
(0.01)
 5.04 
(0.05)
17INBX Inhibrx Biosciences,
176.38 M
 0.04 
 4.05 
 0.17 
18VKTX Viking Therapeutics
155.02 M
 0.04 
 4.65 
 0.19 
19MNKD MannKind Corp
154.16 M
(0.15)
 2.63 
(0.40)
20MEIP MEI Pharma
153.25 M
 0.04 
 3.14 
 0.12 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).